查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571426

切片检查市场规模、份额、趋势分析报告：按产品、类型、应用、地区和细分市场预测，2024-2030

Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Core Needle Biopsy), By Application (Breast Cancer, Lung Cancer), By Product (Kits & Consumables, Instruments), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

癌症切片检查市场的成长和趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球切片检查市场规模预计将达到516.1亿美元，2024年至2030年复合年增长率为8.11%。

分子医学的进步促进了癌症分子表征新仪器的发展。因此，液态切片的接受度和核准不断提高预计将成为整体市场成长的主要动力。

许多新兴製造商致力于开发可以改进基于内视镜检查的癌症切片检查的设备。例如，2023年3月，瑞典公司BiBBInstruments AB以EndoDrill品牌在切片检查市场站稳了脚步。结合现有的切片检查仪器，该公司切片检查仪器进行了改进，以便能够快速、准确地诊断癌症患者。此外，我们还提供与粗针切片和软式内视镜切片检查相容的切片检查仪器。开拓这些新兴市场的公司预计将增加切片检查设备的可及性。

随着液态切片的出现，基于肿瘤学的基因组资料分析和个人化医疗领域预计将显示出良好的前景。由于液态切片提供的巨大潜力，监管机构正在积极支持这些产品的商业化并促进其在临床实践中的使用。液态切片有助于透过各种体液检测癌症，该技术的进步使其成为一种有吸引力的非侵入性方法，用于获取用于诊断目的的癌症生物材料。

在生物製药製造和基因组资料分析公司的重大投资和战略努力的推动下，液态切片领域预计将在未来几年迅速扩张。新兴企业表现出与 QIAGEN Bioinformatics、Fabric Genomics、Agilent Technologies 和 SOPHiA Genetics 等现有产业参与者建立伙伴关係的强烈意愿。这种合作研究趋势预计将进一步推动整体市场成长。

癌症切片检查市场报告亮点

  • 到 2023 年，套件和消耗品按产品占据最大市场占有率，预计这种主导地位将在整个预测期内持续下去。套件和耗材的采用增加是由于肿瘤切片检查向液体切片检查的显着转变。
  • 组织切片检查仍然是切片检查过程的基石，并广泛用于各种诊断应用。此外，肿瘤切片检查主要用于个体层面的诊断和监测正在进行的肿瘤治疗的有效性。
  • 从应用来看，乳癌将在 2023 年主导全球市场，并预计在预测期内保持领先地位。开放性手术切片检查仍然是评估可疑乳房病变患者的黄金标准，因为它在诊断此类疾病方面具有明确的准确性。因此，该部门的收益因其在诊断乳房病变方面已被证实的有效性而得到加强。
  • 由于活跃组织和癌症基金会的集中，北美在 2023 年占据了最大的收益占有率。美国政府组织和私人癌症基金会的强大网络对该地区的产生收入能力做出了重大贡献。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章癌症切片检查市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 癌症切片检查市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章癌症切片检查市场：产品评估与趋势分析

  • 全球癌症切片检查市场：产品仪表板
  • 全球癌症切片检查市场：产品变异分析
  • 按产品分類的收益
  • 装置
  • 套件和用品
  • 服务

第五章癌症切片检查市场：类型估计和趋势分析

  • 全球癌症切片检查市场：类型仪表板
  • 全球癌症切片检查市场：类型变异分析
  • 按类型分類的收益
  • 组织切片检查
  • 液态生物检体
  • 其他的

第六章癌症切片检查市场：应用估算与趋势分析

  • 全球癌症切片检查市场：应用仪表板
  • 全球癌症切片检查市场：应用变化分析
  • 按使用量和收益
  • 乳癌
  • 大肠直肠癌
  • 子宫颈癌
  • 肺癌
  • 摄护腺癌
  • 皮肤癌
  • 血癌
  • 肾癌
  • 肝癌
  • 胰臟癌
  • 卵巢癌
  • 其他的

第七章癌症切片检查市场：按类型、产品、应用和应用的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • Key customers
    • Key company market share analysis, 2023
    • QIAGEN
    • Illumina, Inc.
    • ANGLE plc
    • BD（Becton, Dickinson and Company）
    • Myriad Genetics, Inc.
    • Hologic, Inc.
    • Biocept, Inc.
    • Thermo Fisher Scientific, Inc.
    • Danaher
    • F. Hoffmann-La Roche Ltd.
    • Lucence Health Inc.
    • GRAIL, Inc.
    • Guardant Health Inc.
    • Exact Sciences Corporation
    • Freenome Holdings, Inc.
    • Biodesix（Integrated Diagnostics）
    • Oncimmune
    • Epigenomics AG
    • HelioHealth（Laboratory for Advanced Medicine）
    • Genesystems, Inc.（Genesys Biolabs）
    • Chronix Biomedical, Inc.
    • Personal Genome Diagnostics Inc.
    • Natera, Inc.
    • Personalis Inc.
Product Code: GVR-4-68039-254-2

Cancer Biopsy Market Growth & Trends:

The global cancer biopsy market size is expected to reach USD 51.61 billion by 2030, registering a CAGR of 8.11% from 2024 to 2030, according to a new report by Grand View Research, Inc. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.

Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.

The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.

The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.

Cancer Biopsy Market Report Highlights:

  • In 2023, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies.
  • Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments.
  • In terms of application, breast cancer dominated the global market in 2023 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis.
  • North America held the largest revenue share in 2023 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Type
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and type outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Biopsy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Advent of liquid biopsy
      • 3.2.1.2. Transition of novel oncology diagnostics from bench to clinics
      • 3.2.1.3. Advancements in quality and payment pertaining to genetic cancer tests
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risks associated with biopsy procedures
      • 3.2.2.2. Technical and clinical challenges
  • 3.3. Cancer Biopsy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cancer Biopsy Market: Product Estimates & Trend Analysis

  • 4.1. Global Cancer Biopsy Market: Product Dashboard
  • 4.2. Global Cancer Biopsy Market: Product Movement Analysis
  • 4.3. Global Cancer Biopsy Market by Product, Revenue
  • 4.4. Instruments
    • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Kits and Consumables
    • 4.5.1. Kits and consumables market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.6. Services
    • 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Cancer Biopsy Market: Type Estimates & Trend Analysis

  • 5.1. Global Cancer Biopsy Market: Type Dashboard
  • 5.2. Global Cancer Biopsy Market: Type Movement Analysis
  • 5.3. Global Cancer Biopsy Market by Type, Revenue
  • 5.4. Tissue Biopsies
    • 5.4.1. Tissue biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Needle Biopsies
    • 5.4.3. Needle biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.4. Fine Needle Aspiration (FNA)
      • 5.4.4.1. Fine Needle Aspiration (FNA) market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.5. Core Needle Biopsy (CNB)
      • 5.4.5.1. Core Needle Biopsy (CNB) market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.6. Surgical Biopsies
    • 5.4.7. Surgical biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Liquid Biopsies
    • 5.5.1. Liquid biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Cancer Biopsy Market: Application Estimates & Trend Analysis

  • 6.1. Global Cancer Biopsy Market: Application Dashboard
  • 6.2. Global Cancer Biopsy Market: Application Movement Analysis
  • 6.3. Global Cancer Biopsy Market by Application, Revenue
  • 6.4. Breast Cancer
    • 6.4.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Colorectal Cancer
    • 6.5.1. Colorectal cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Cervical Cancer
    • 6.6.1. Cervical cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. Lung Cancer
    • 6.7.1. Lung cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8. Prostate Cancer
    • 6.8.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9. Skin Cancer
    • 6.9.1. Skin cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.10. Blood Cancer
    • 6.10.1. Blood cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.11. Kidney Cancer
    • 6.11.1. Kidney cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.12. Liver Cancer
    • 6.12.1. Liver cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.13. Pancreatic Cancer
    • 6.13.1. Pancreatic cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.14. Ovarian Cancer
    • 6.14.1. Ovarian cancer market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.15. Others
    • 6.15.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Cancer Biopsy Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End-use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. QIAGEN
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Illumina, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. ANGLE plc
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. BD (Becton, Dickinson and Company)
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Myriad Genetics, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Hologic, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Biocept, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Thermo Fisher Scientific, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Danaher
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. F. Hoffmann-La Roche Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Lucence Health Inc.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. GRAIL, Inc.
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Guardant Health Inc.
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives
    • 8.3.17. Exact Sciences Corporation
      • 8.3.17.1. Company overview
      • 8.3.17.2. Financial performance
      • 8.3.17.3. Product benchmarking
      • 8.3.17.4. Strategic initiatives
    • 8.3.18. Freenome Holdings, Inc.
      • 8.3.18.1. Company overview
      • 8.3.18.2. Financial performance
      • 8.3.18.3. Product benchmarking
      • 8.3.18.4. Strategic initiatives
    • 8.3.19. Biodesix (Integrated Diagnostics)
      • 8.3.19.1. Company overview
      • 8.3.19.2. Financial performance
      • 8.3.19.3. Product benchmarking
      • 8.3.19.4. Strategic initiatives
    • 8.3.20. Oncimmune
      • 8.3.20.1. Company overview
      • 8.3.20.2. Financial performance
      • 8.3.20.3. Product benchmarking
      • 8.3.20.4. Strategic initiatives
    • 8.3.21. Epigenomics AG
      • 8.3.21.1. Company overview
      • 8.3.21.2. Financial performance
      • 8.3.21.3. Product benchmarking
      • 8.3.21.4. Strategic initiatives
    • 8.3.22. HelioHealth (Laboratory for Advanced Medicine)
      • 8.3.22.1. Company overview
      • 8.3.22.2. Financial performance
      • 8.3.22.3. Product benchmarking
      • 8.3.22.4. Strategic initiatives
    • 8.3.23. Genesystems, Inc. (Genesys Biolabs)
      • 8.3.23.1. Company overview
      • 8.3.23.2. Financial performance
      • 8.3.23.3. Product benchmarking
      • 8.3.23.4. Strategic initiatives
    • 8.3.24. Chronix Biomedical, Inc.
      • 8.3.24.1. Company overview
      • 8.3.24.2. Financial performance
      • 8.3.24.3. Product benchmarking
      • 8.3.24.4. Strategic initiatives
    • 8.3.25. Personal Genome Diagnostics Inc.
      • 8.3.25.1. Company overview
      • 8.3.25.2. Financial performance
      • 8.3.25.3. Product benchmarking
      • 8.3.25.4. Strategic initiatives
    • 8.3.26. Natera, Inc.
      • 8.3.26.1. Company overview
      • 8.3.26.2. Financial performance
      • 8.3.26.3. Product benchmarking
      • 8.3.26.4. Strategic initiatives
    • 8.3.27. Personalis Inc.
      • 8.3.27.1. Company overview
      • 8.3.27.2. Financial performance
      • 8.3.27.3. Product benchmarking
      • 8.3.27.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 4 Global Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 5 Global Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 6 Global Cancer Biopsy Market, by Region, 2018 - 2030 (USD Billion)
  • Table 7 North America Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
  • Table 8 North America Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 9 North America Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 10 North America Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 11 U.S. Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 12 U.S. Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 13 U.S. Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 14 Canada Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 15 Canada Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 16 Canada Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 17 Mexico Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 18 Mexico Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 19 Mexico Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 20 Europe Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
  • Table 21 Europe Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 22 Europe Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 23 Europe Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 24 Germany Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 25 Germany Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 26 Germany Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 27 UK Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 28 UK Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 29 UK Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 30 France Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 31 France Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 32 France Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 33 Italy Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 34 Italy Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 35 Italy Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 36 Spain Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 37 Spain Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 38 Spain Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 39 Denmark Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 40 Denmark Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 41 Denmark Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 42 Sweden Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 43 Sweden Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 44 Sweden Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 45 Norway Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 46 Norway Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 47 Norway Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 48 Asia Pacific Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
  • Table 49 Asia Pacific Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 50 Asia Pacific Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 51 Asia Pacific Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 52 China Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 53 China Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 54 China Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 55 Japan Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 56 Japan Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 57 Japan Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 58 India Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 59 India Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 60 India Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 61 South Korea Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 62 South Korea Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 63 South Korea Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 64 Australia Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 65 Australia Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 66 Australia Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 67 Thailand Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 68 Thailand Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 69 Thailand Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 70 Latin America Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
  • Table 71 Latin America Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 72 Latin America Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 73 Latin America Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 74 Brazil Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 75 Brazil Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 76 Brazil Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 77 Argentina Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 78 Argentina Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 79 Argentina Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 80 Middle East & Africa Cancer Biopsy Market, by Country, 2018 - 2030 (USD Billion)
  • Table 81 Middle East & Africa Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 82 Middle East & Africa Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 83 Middle East & Africa Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 84 South Africa Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 85 South Africa Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 86 South Africa Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 87 Saudi Arabia Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 88 Saudi Arabia Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 89 Saudi Arabia Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 90 UAE Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 91 UAE Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 92 UAE Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)
  • Table 93 Kuwait Cancer Biopsy Market, by Product, 2018 - 2030 (USD Billion)
  • Table 94 Kuwait Cancer Biopsy Market, by Type, 2018 - 2030 (USD Billion)
  • Table 95 Kuwait Cancer Biopsy Market, by Application, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Cancer Biopsy Market Segmentation
  • Fig. 8 Market Snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Global Cancer Biopsy Market: Product & Services Movement Analysis
  • Fig. 16 Global Cancer Biopsy Market, for Instruments, 2018 - 2030 (USD Billion)
  • Fig. 17 Global Cancer Biopsy Market, for Kits and Consumables, 2018 - 2030 (USD Billion)
  • Fig. 18 Global Cancer Biopsy Market, for Services, 2018 - 2030 (USD Billion)
  • Fig. 19 Global Cancer Biopsy Market: Type Movement Analysis
  • Fig. 20 Global Cancer Biopsy Market, for Tissue Biopsies, 2018 - 2030 (USD Billion)
  • Fig. 21 Global Cancer Biopsy Market, for Liquid Biopsies, 2018 - 2030 (USD Billion)
  • Fig. 22 Global Cancer Biopsy Market, for Other, 2018 - 2030 (USD Billion)
  • Fig. 23 Global Cancer Biopsy Market: Application Movement Analysis
  • Fig. 24 Global Cancer Biopsy Market, for Breast Cancer, 2018 - 2030 (USD Billion)
  • Fig. 25 Global Cancer Biopsy Market, for Colorectal Cancer, 2018 - 2030 (USD Billion)
  • Fig. 26 Global Cancer Biopsy Market, for Cervical Cancer, 2018 - 2030 (USD Billion)
  • Fig. 27 Global Cancer Biopsy Market, for Lung Cancer, 2018 - 2030 (USD Billion)
  • Fig. 28 Global Cancer Biopsy Market, for Prostate Cancer, 2018 - 2030 (USD Billion)
  • Fig. 29 Global Cancer Biopsy Market, for Skin Cancer, 2018 - 2030 (USD Billion)
  • Fig. 30 Global Cancer Biopsy Market, for Blood Cancer, 2018 - 2030 (USD Billion)
  • Fig. 31 Global Cancer Biopsy Market, for Kidney Cancer, 2018 - 2030 (USD Billion)
  • Fig. 32 Global Cancer Biopsy Market, for Liver Cancer, 2018 - 2030 (USD Billion)
  • Fig. 33 Global Cancer Biopsy Market, for Pancreatic Cancer, 2018 - 2030 (USD Billion)
  • Fig. 34 Global Cancer Biopsy Market, for Ovarian Cancer, 2018 - 2030 (USD Billion)
  • Fig. 35 Global Cancer Biopsy Market, for Others, 2018 - 2030 (USD Billion)
  • Fig. 36 Regional Marketplace: Key Takeaways
  • Fig. 37 Regional Outlook, 2023 & 2030
  • Fig. 38 Global Cancer Biopsy Market: Region Movement Analysis
  • Fig. 39 North America Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 40 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 41 Canada Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 42 Mexico Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 43 Europe Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 44 Germany Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 45 UK Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 46 France Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 47 Italy Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 48 Spain Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 49 Denmark Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 50 Sweden Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 51 Norway Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 52 Asia Pacific Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 53 Japan Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 54 China Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 55 India Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 56 Australia Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 57 South Korea Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 58 Thailand Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 59 Latin America Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 60 Brazil Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 61 Argentina Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 62 Middle East and Africa Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 63 South Africa Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 64 Saudi Arabia Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 65 UAE Cancer Biopsy Market, 2018 - 2030 (USD Billion)
  • Fig. 66 Kuwait Cancer Biopsy Market, 2018 - 2030 (USD Billion)